Goldman Sachs’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $89.9M | Buy |
165,979
+51,560
| +45% | +$29M | 0.01% | 1304 |
|
|
2026
Q1 | $67.8M | Buy |
114,419
+3,645
| +3% | +$1.82M | 0.01% | 1328 |
|
|
2025
Q4 | $54M | Buy |
110,774
+29,238
| +36% | +$13.6M | 0.01% | 1448 |
|
|
2025
Q3 | $34.2M | Sell |
81,536
-66,662
| -45% | -$22.4M | ﹤0.01% | 1751 |
|
|
2025
Q2 | $42.6M | Buy |
148,198
+71,842
| +94% | +$21.5M | 0.01% | 1448 |
|
|
2025
Q1 | $23.5M | Sell |
76,356
-19,979
| -21% | -$6.85M | ﹤0.01% | 1872 |
|
|
2024
Q4 | $34M | Buy |
96,335
+18,997
| +25% | +$6.98M | 0.01% | 1612 |
|
|
2024
Q3 | $27.7M | Sell |
77,338
-3,372
| -4% | -$1.14M | ﹤0.01% | 1763 |
|
|
2024
Q2 | $25.7M | Buy |
80,710
+22,234
| +38% | +$5.88M | ﹤0.01% | 1684 |
|
|
2024
Q1 | $13.4M | Sell |
58,476
-47,653
| -45% | -$10.8M | ﹤0.01% | 2195 |
|
|
2023
Q4 | $23.3M | Sell |
106,129
-9,060
| -8% | -$2.09M | ﹤0.01% | 1759 |
|
|
2023
Q3 | $26M | Sell |
115,189
-71,814
| -38% | -$16.5M | 0.01% | 1581 |
|
|
2023
Q2 | $41.3M | Buy |
187,003
+51,557
| +38% | +$11.4M | 0.01% | 1245 |
|
|
2023
Q1 | $30.3M | Sell |
135,446
-176,693
| -57% | -$43.6M | 0.01% | 1446 |
|
|
2022
Q4 | $86.8M | Buy |
312,139
+117,912
| +61% | +$29.8M | 0.02% | 802 |
|
|
2022
Q3 | $40.7M | Sell |
194,227
-13,265
| -6% | -$2.97M | 0.01% | 1265 |
|
|
2022
Q2 | $48.9M | Buy |
207,492
+34,164
| +20% | +$6.95M | 0.01% | 1136 |
|
|
2022
Q1 | $31.1M | Buy |
173,328
+4,255
| +3% | +$811K | 0.01% | 1692 |
|
|
2021
Q4 | $36.5M | Sell |
169,073
-113,763
| -40% | -$22.3M | 0.01% | 1604 |
|
|
2021
Q3 | $52.2M | Buy |
282,836
+81,882
| +41% | +$16.1M | 0.01% | 1257 |
|
|
2021
Q2 | $36.1M | Sell |
200,954
-122,411
| -38% | -$23.3M | 0.01% | 1543 |
|
|
2021
Q1 | $54.1M | Sell |
323,365
-63,376
| -16% | -$10.6M | 0.01% | 1122 |
|
|
2020
Q4 | $58.7M | Sell |
386,741
-45,171
| -10% | -$5.93M | 0.02% | 1000 |
|
|
2020
Q3 | $43.6M | Buy |
431,912
+197,884
| +85% | +$21.7M | 0.01% | 1106 |
|
|
2020
Q2 | $28.3M | Sell |
234,028
-246,515
| -51% | -$27.7M | 0.01% | 1401 |
|
|
2020
Q1 | $45.6M | Buy |
480,543
+113,845
| +31% | +$10.8M | 0.02% | 933 |
|
|
2019
Q4 | $32.3M | Buy |
366,698
+106,157
| +41% | +$9.34M | 0.01% | 1477 |
|
|
2019
Q3 | $20.8M | Sell |
260,541
-406,233
| -61% | -$32.7M | 0.01% | 1740 |
|
|
2019
Q2 | $52M | Sell |
666,774
-152,619
| -19% | -$14.3M | 0.02% | 1108 |
|
|
2019
Q1 | $96.2M | Sell |
819,393
-100,472
| -11% | -$11.7M | 0.03% | 686 |
|
|
2018
Q4 | $100M | Sell |
919,865
-198,776
| -18% | -$23M | 0.03% | 612 |
|
|
2018
Q3 | $143M | Buy |
1,118,641
+198,097
| +22% | +$24.5M | 0.04% | 549 |
|
|
2018
Q2 | $104M | Sell |
920,544
-104,246
| -10% | -$11.5M | 0.03% | 701 |
|
|
2018
Q1 | $115M | Sell |
1,024,790
-6,444
| -0.6% | -$819K | 0.03% | 689 |
|
|
2017
Q4 | $153M | Sell |
1,031,234
-103,445
| -9% | -$13.2M | 0.04% | 585 |
|
|
2017
Q3 | $133M | Sell |
1,134,679
-440,736
| -28% | -$56.3M | 0.03% | 644 |
|
|
2017
Q2 | $204M | Buy |
1,575,415
+420,594
| +36% | +$52.5M | 0.05% | 396 |
|
|
2017
Q1 | $156M | Buy |
1,154,821
+282,955
| +32% | +$42.9M | 0.04% | 486 |
|
|
2016
Q4 | $125M | Buy |
871,866
+76,227
| +10% | +$9.73M | 0.04% | 632 |
|
|
2016
Q3 | $93.9M | Sell |
795,639
-257,614
| -24% | -$31M | 0.03% | 755 |
|
|
2016
Q2 | $112M | Buy |
1,053,253
+82,735
| +9% | +$9.23M | 0.04% | 603 |
|
|
2016
Q1 | $108M | Buy |
970,518
+54,830
| +6% | +$6.94M | 0.04% | 621 |
|
|
2015
Q4 | $143M | Buy |
915,688
+390,383
| +74% | +$56.8M | 0.05% | 485 |
|
|
2015
Q3 | $68.9M | Sell |
525,305
-6,201
| -1% | -$995K | 0.02% | 845 |
|
|
2015
Q2 | $92.5M | Buy |
531,506
+69,672
| +15% | +$12.5M | 0.03% | 702 |
|
|
2015
Q1 | $79.6M | Buy |
461,834
+173,206
| +60% | +$26.4M | 0.03% | 777 |
|
|
2014
Q4 | $37.4M | Sell |
288,628
-40,168
| -12% | -$5.18M | 0.01% | 1342 |
|
|
2014
Q3 | $42.3M | Sell |
328,796
-231,207
| -41% | -$23.8M | 0.01% | 1196 |
|
|
2014
Q2 | $49.6M | Buy |
560,003
+173,845
| +45% | +$16.7M | 0.02% | 1105 |
|
|
2014
Q1 | $36.3M | Sell |
386,158
-116,385
| -23% | -$11.9M | 0.01% | 1284 |
|
|
2013
Q4 | $56.8M | Buy |
502,543
+113,585
| +29% | +$10.2M | 0.02% | 959 |
|
|
2013
Q3 | $30.7M | Sell |
388,958
-29,565
| -7% | -$2.16M | 0.01% | 1306 |
|
|
2013
Q2 | $27.5M | Buy |
+418,523
| New | +$27M | 0.01% | 1296 |
|
Other funds holding UTHR
ACA
JT
Goldman Sachs's UTHR Position: Q2 2026 in Review
Goldman Sachs increased its United Therapeutics (UTHR) stake by 45% in Q2 2026, buying an estimated $29M and bringing the position to 165,979 shares worth $89.9M. The position accounts for 0.01% of the portfolio, ranked #1304.
Goldman Sachs first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $204M in Q2 2017. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Goldman Sachs held 165,979 shares of United Therapeutics worth $89.9M as of Q2 2026.
- Goldman Sachs bought 51,560 United Therapeutics shares in Q2 2026, an estimated $29M.
- United Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1304 holding.
- Goldman Sachs first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Goldman Sachs's United Therapeutics position peaked at $204M in Q2 2017.
- 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.